menu
    • menu
    [{"orgOrder":0,"company":"LifeBridge Health","sponsor":"HAEMONETICS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase IV","graph3":"LifeBridge Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeBridge Health \/ Haemonetics","highestDevelopmentStatusID":"11","companyTruncated":"LifeBridge Health \/ Haemonetics"},{"orgOrder":0,"company":"Wayne State University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Wayne State University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wayne State University \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Wayne State University \/ GSK"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.76000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Aspen Pharmacare Holdings \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Viatris"},{"orgOrder":0,"company":"Duke University","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin-III","graph1":"Nephrology","graph2":"Phase I","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duke University \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Duke University \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals for Fondaparinux Sodium

    Menu

    Fondaparinux Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen Pharmacare Holdings

                            South Africa
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Viatris

                            Deal Size : $757.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary

                            Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

                            Product Name : Arixtra

                            Product Type : Miscellaneous

                            Upfront Cash : $310.4 million

                            September 08, 2020

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Viatris

                            Deal Size : $757.2 million

                            Deal Type : Acquisition

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LifeBridge Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            LifeBridge Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : HAEMONETICS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthro...

                            Details : Arixtra is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2013

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : HAEMONETICS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wayne State University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Wayne State University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fondaparinux in Critically Ill Patients With Renal Failure

                            Details : Fondaparinux is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thromboembolism.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 08, 2011

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

                            Details : Fondaparinux Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2010

                            Lead Product(s) : Fondaparinux Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth